Cefuroxime | Cefuroxime Kabi bottles 750 mg, 10 pcs.
Special Price
$35.89
Regular Price
$44.00
In stock
SKU
BID471929
Latin name
Cefuroxime
Cefuroxime
Latin name
Cefuroxime
Release form
Powder for solution for intravenous and intramuscular administration
Packing
10 vials.
Pharmacological action of
Cefuroxime is a second-generation cephalosporin antibiotic.
Cefuroxime is active against a wide range of pathogens, including strains producing -lactamases.
The bactericidal action of cefuroxime is associated with inhibition of bacterial cell wall synthesis.
Indications
Bacterial infections caused by cefuroxime-sensitive microorganisms: - diseases of the respiratory tract (bronchitis, pneumonia, lung abscess, pleural empyema)
- ENT organs (sinusitis, tonsillitis, pharyngitis, otitis media, urinary tract infections cystitis, asymptomatic bacteriuria)
- skin and soft tissues (erysipelas, pyoderma, impetigo, furunculosis, phlegmon, wound infection, erysipeloid)
- bones and joints (osteomyelitis, septic arthritis)
- organs of small bowel disease, adrenal gland disease (cervitis)
- sepsis
- meningitis
- gonorrhea
- Lyme disease (borreliosis)
- prevention of infectious complications in operations on the organs of the chest, abdomen, pelvis, joints (including lung, heart, esophagus, in vascular surgery at high risk of infection nnyh complications in orthopedic surgery).
Contraindications
Hypersensitivity to cefuroxime (including other cephalosporins, penicillins and carbapenems).
Precautions
Neonatal period, prematurity, chronic renal failure, bleeding and diseases of the gastrointestinal tract (including a history of ulcerative colitis), debilitated and malnourished patients, pregnancy, lactation, simultaneous use with aminoglycosides, "loop" diuretics.
Use during pregnancy and lactation
Use of the drug during pregnancy and during breastfeeding is possible if the expected benefit to the mother outweighs the potential risk to the fetus and the baby.
Composition
1 vial contains: active ingredient: cefuroxime sodium (in terms of cefuroxime) - 0.75 g
ethe on cefuroxime) - 0.75 g
Dosage and administration of
Intramuscularly, intravenously.
Intravenously and intramuscularly, adults are prescribed 0.75 g 3 times a day for severe infections - the dose is increased to 1. 5 g 3-4 times a day (if necessary, the interval between administrations can be reduced to 6 hours). The average daily dose is 3-6 g.
Children older than 3 months are prescribed 30-100 mg / kg / day in 3-4 injections. For most infections, the optimal dose is 60 mg / kg / day.
Newborns and children up to 3 months of age are prescribed 30 mg / kg / day in 2–3 administrations.
In case of gonorrhea - intramuscularly, adults 1.5 g once (in the form of 2 injections of 0.75 g with the introduction in different areas, for example, in both gluteal muscles).
In case of bacterial meningitis - intravenously, for adults - 3 g every 8 hours for children of younger and older age - 150-250 mg / kg / day in 3-4 injections, for newborns - 100 mg / kg / day in 2-3 injections.
For the prevention of postoperative complications: - for operations on the heart, lungs, esophagus and blood vessels - intravenously, 1.5 g 0.5 to 1 hour before surgery and 0. 75 g intravenously or intramuscularly every 8 hours for prolonged operations for the next 24 to 48 hours (for open heart surgery, the total dose is up to 6 g)
- for operations on the abdominal cavity, pelvic organs and orthopedic operations - intravenously, 1.5 g for induction of anesthesia, then additionally - intramuscularly, 0.75 g, after 8 and 16 hours after
operation - with a complete joint replacement - 1.5 g of powder is mixed in dry form with each packet of methyl methacrylate cement polymer before adding liquid monomer.
In pneumonia - intramuscularly or intravenously, 1.5 g 2-3 times a day for 48-72 hours, then they switch to oral administration (use dosage forms for oral administration) 0.5 g 2 times a day for 7- 10 days.
When exacerbation of chronic bronchitis is prescribed intramuscularly or intravenously, at 0. 75 g 2-3 times a day for 48-72 hours, then switch to oral administration (use dosage forms for oral administration) 0.5 g 2 times a day for 5-10 days.
In chronic renal failure, correction of the dosage regimen in adults is necessary: with creatinine clearance (CC) 10-20 ml / min is prescribed intravenously or intramuscularly at 0.75 g 2 times a day, with CC less than 10 ml / min - at 0.75 g 1 time per day.
In chronic renal failure in children, the dosage regimen should be changed in accordance with the recommendations for adults.
Patients undergoing continuous hemodialysis using an arteriovenous shunt or high-speed hemofiltration in intensive care units are prescribed 0.75 g 2 times a day for patients who are on low-speed hemofiltration, they are prescribed recommended for impaired renal function.
Side effects
Allergic reactions: chills, rash, itching, urticaria, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospasm, drug-induced fever, serum fever, cutaneous vasculitis.
Local reactions: with intramuscular administration - pain, irritation and infiltration at the injection site, with intravenous administration - phlebitis, thrombophlebitis.
From the nervous system: cramps.
From the genitourinary system: itching in the perineum, vaginitis.
From the urinary system: impaired renal function (with an increase in the concentration of creatinine and / or urea nitrogen and a decrease in creatinine clearance), dysuria, interstitial nephritis.
From the digestive system: diarrhea, constipation, flatulence, glossitis, nausea, vomiting, cramping and abdominal pain, ulceration of the oral mucosa, oral candidiasis, cholestasis, pseudomembranous colitis.
From the hemopoietic organs: eosinophilia, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hemolytic anemia, decreased hemoglobin and hematocrit, hypoprothrombinemia, lengthening of prothrombin time.
Sensory organs: hearing loss.
Laboratory indicators: increased activity of hepatic enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase), hyperbilirubinemia, false positive Coombs test.
Drug Interaction
Concurrent administration of loop diuretics slows tubular secretion, decreases renal clearance, increases plasma concentration, and increases the half-life of cefuroxime.
When used with aminoglycosides and diuretics, the risk of nephrotoxic effects is increased.
Pharmaceutically compatible with aqueous solutions containing up to 1% lidocaine hydrochloride, 0.9% sodium chloride solution, 5 and 10% dextrose solution, 0.18% sodium chloride solution and 4% dextrose solution, 5% dextrose solution and 0.9% sodium chloride solution Ringer, Hartman's solution, sodium lactate solution, heparin (10 U / ml and 50 U / ml) in 0.9% sodium chloride solution.
Pharmaceutically incompatible with aminoglycosides, sodium carbonate solution 2.74%.
Overdose
Symptoms: excitation of the central nervous system, convulsions.
Treatment: symptomatic, hemodialysis, peritoneal dialysis.
Storage conditions
In a dry, dark place at a temperature of no higher than 25 РC.
Expiration
2 years.
Deystvuyuschee substances
Cefuroxime
Dosage form
dosage form
injection solution
Fresenius Kabi, Germany
Cefuroxime
Release form
Powder for solution for intravenous and intramuscular administration
Packing
10 vials.
Pharmacological action of
Cefuroxime is a second-generation cephalosporin antibiotic.
Cefuroxime is active against a wide range of pathogens, including strains producing -lactamases.
The bactericidal action of cefuroxime is associated with inhibition of bacterial cell wall synthesis.
Indications
Bacterial infections caused by cefuroxime-sensitive microorganisms: - diseases of the respiratory tract (bronchitis, pneumonia, lung abscess, pleural empyema)
- ENT organs (sinusitis, tonsillitis, pharyngitis, otitis media, urinary tract infections cystitis, asymptomatic bacteriuria)
- skin and soft tissues (erysipelas, pyoderma, impetigo, furunculosis, phlegmon, wound infection, erysipeloid)
- bones and joints (osteomyelitis, septic arthritis)
- organs of small bowel disease, adrenal gland disease (cervitis)
- sepsis
- meningitis
- gonorrhea
- Lyme disease (borreliosis)
- prevention of infectious complications in operations on the organs of the chest, abdomen, pelvis, joints (including lung, heart, esophagus, in vascular surgery at high risk of infection nnyh complications in orthopedic surgery).
Contraindications
Hypersensitivity to cefuroxime (including other cephalosporins, penicillins and carbapenems).
Precautions
Neonatal period, prematurity, chronic renal failure, bleeding and diseases of the gastrointestinal tract (including a history of ulcerative colitis), debilitated and malnourished patients, pregnancy, lactation, simultaneous use with aminoglycosides, "loop" diuretics.
Use during pregnancy and lactation
Use of the drug during pregnancy and during breastfeeding is possible if the expected benefit to the mother outweighs the potential risk to the fetus and the baby.
Composition
1 vial contains: active ingredient: cefuroxime sodium (in terms of cefuroxime) - 0.75 g
ethe on cefuroxime) - 0.75 g
Dosage and administration of
Intramuscularly, intravenously.
Intravenously and intramuscularly, adults are prescribed 0.75 g 3 times a day for severe infections - the dose is increased to 1. 5 g 3-4 times a day (if necessary, the interval between administrations can be reduced to 6 hours). The average daily dose is 3-6 g.
Children older than 3 months are prescribed 30-100 mg / kg / day in 3-4 injections. For most infections, the optimal dose is 60 mg / kg / day.
Newborns and children up to 3 months of age are prescribed 30 mg / kg / day in 2–3 administrations.
In case of gonorrhea - intramuscularly, adults 1.5 g once (in the form of 2 injections of 0.75 g with the introduction in different areas, for example, in both gluteal muscles).
In case of bacterial meningitis - intravenously, for adults - 3 g every 8 hours for children of younger and older age - 150-250 mg / kg / day in 3-4 injections, for newborns - 100 mg / kg / day in 2-3 injections.
For the prevention of postoperative complications: - for operations on the heart, lungs, esophagus and blood vessels - intravenously, 1.5 g 0.5 to 1 hour before surgery and 0. 75 g intravenously or intramuscularly every 8 hours for prolonged operations for the next 24 to 48 hours (for open heart surgery, the total dose is up to 6 g)
- for operations on the abdominal cavity, pelvic organs and orthopedic operations - intravenously, 1.5 g for induction of anesthesia, then additionally - intramuscularly, 0.75 g, after 8 and 16 hours after
operation - with a complete joint replacement - 1.5 g of powder is mixed in dry form with each packet of methyl methacrylate cement polymer before adding liquid monomer.
In pneumonia - intramuscularly or intravenously, 1.5 g 2-3 times a day for 48-72 hours, then they switch to oral administration (use dosage forms for oral administration) 0.5 g 2 times a day for 7- 10 days.
When exacerbation of chronic bronchitis is prescribed intramuscularly or intravenously, at 0. 75 g 2-3 times a day for 48-72 hours, then switch to oral administration (use dosage forms for oral administration) 0.5 g 2 times a day for 5-10 days.
In chronic renal failure, correction of the dosage regimen in adults is necessary: with creatinine clearance (CC) 10-20 ml / min is prescribed intravenously or intramuscularly at 0.75 g 2 times a day, with CC less than 10 ml / min - at 0.75 g 1 time per day.
In chronic renal failure in children, the dosage regimen should be changed in accordance with the recommendations for adults.
Patients undergoing continuous hemodialysis using an arteriovenous shunt or high-speed hemofiltration in intensive care units are prescribed 0.75 g 2 times a day for patients who are on low-speed hemofiltration, they are prescribed recommended for impaired renal function.
Side effects
Allergic reactions: chills, rash, itching, urticaria, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospasm, drug-induced fever, serum fever, cutaneous vasculitis.
Local reactions: with intramuscular administration - pain, irritation and infiltration at the injection site, with intravenous administration - phlebitis, thrombophlebitis.
From the nervous system: cramps.
From the genitourinary system: itching in the perineum, vaginitis.
From the urinary system: impaired renal function (with an increase in the concentration of creatinine and / or urea nitrogen and a decrease in creatinine clearance), dysuria, interstitial nephritis.
From the digestive system: diarrhea, constipation, flatulence, glossitis, nausea, vomiting, cramping and abdominal pain, ulceration of the oral mucosa, oral candidiasis, cholestasis, pseudomembranous colitis.
From the hemopoietic organs: eosinophilia, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, hemolytic anemia, decreased hemoglobin and hematocrit, hypoprothrombinemia, lengthening of prothrombin time.
Sensory organs: hearing loss.
Laboratory indicators: increased activity of hepatic enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase), hyperbilirubinemia, false positive Coombs test.
Drug Interaction
Concurrent administration of loop diuretics slows tubular secretion, decreases renal clearance, increases plasma concentration, and increases the half-life of cefuroxime.
When used with aminoglycosides and diuretics, the risk of nephrotoxic effects is increased.
Pharmaceutically compatible with aqueous solutions containing up to 1% lidocaine hydrochloride, 0.9% sodium chloride solution, 5 and 10% dextrose solution, 0.18% sodium chloride solution and 4% dextrose solution, 5% dextrose solution and 0.9% sodium chloride solution Ringer, Hartman's solution, sodium lactate solution, heparin (10 U / ml and 50 U / ml) in 0.9% sodium chloride solution.
Pharmaceutically incompatible with aminoglycosides, sodium carbonate solution 2.74%.
Overdose
Symptoms: excitation of the central nervous system, convulsions.
Treatment: symptomatic, hemodialysis, peritoneal dialysis.
Storage conditions
In a dry, dark place at a temperature of no higher than 25 РC.
Expiration
2 years.
Deystvuyuschee substances
Cefuroxime
Dosage form
dosage form
injection solution
Fresenius Kabi, Germany
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review